Interview with Ulrich Behrendt, President, VBU
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Address: Theodor-Heuss-Allee 25 D – 60486 Frankfurt am Main,Germany
Tel: 069 / 75 64- 124
VBU – Association of German Biotech Companies was founded in October 1996 on the initiative of 55 biotech companies. VBU now has over 210 corporate members, making it the largest and oldest industrial biotechnology association in Germany.Since its foundation VBU has devoted itself to the promotion of science and technology and the transfer of research findings into innovations. Furthermore VBU works in close collaboration with other national and international organisations from the areas of biotechnology, pharma, and knowledge and technology transfer.VBU is part of DECHEMA e.V. which was founded in 1926. Today DECHEMA has over 5,000 personal and sustaining members from science and industry.DECHEMA pools the know-how of experts, provides strong networks for research and development, is a platform for expert information, communication, and practice-oriented exchange of ideas and experience. DECHEMA is at the interface between science, industry, regulatory bodies and the public.
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. …
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, critiques the draft EU Pharma Regulation…
Merck KGaA’s Marco Rauland and Kaushal Kishore examine how artificial intelligence and machine learning can best be applied in pharmaceutical pricing and market access. Noting the significant uptake of such…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, launches a critique of current pharmaceutical…
The latest pharma industry news from Germany, including German lobbying efforts against EU pharma legislation; Evonik’s new lipid manufacturing plant; Bayer’s 2023 sales and earnings outlook; Boehringer Ingelheim new biotech…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Germany-based pharma and healthcare services group Fresenius has had its share of challenges. After the group’s dialysis division, Fresenius Medical Care (FMC), was hit with a high rate of COVID-19…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
At the recent World Economic Forum in Davos, Chair of the Executive Board and CEO of Merck, Belén Garijo, speaking in a session on workforce transformation in the digital era,…
In response to a looming deficit of EUR 17 billion, Germany’s new Financial Stabilization of Statutory Health Insurance System Act (GKV-Finanzstabilisierungsgesetz, or GKV-FinStG) is aimed at containing costs in the…
See our Cookie Privacy Policy Here